Curcumin liposomal - Signpath Pharma

Drug Profile

Curcumin liposomal - Signpath Pharma

Alternative Names: Diferuloylmethane; Lipocurc; Lipocurcumin; Liposomal curcumin

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Signpath Pharma
  • Class Anti-ischaemics; Antihistamines; Antivirals; Catechols; Chemopreventatives; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action NF-kappa B inhibitors; Proto oncogene protein c-akt inhibitors; Toll-like receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for phase-I development in Solid-tumours(Metastatic disease, Recurrent) in Austria (IV, Infusion)
  • 18 Jul 2016 Development for Solid tumours is ongoing
  • 09 Apr 2015 Signpath Pharma has patent protection for curcumin liposomal in USA (Signpath Pharma form 10-K, April 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top